SUPPLEMENT DATED 6 NOVEMBER 2023
TO THE REGISTRATION DOCUMENT OF 7 FEBRUARY 2023

BioSenic SA (the "**Company**" or "**BioSenic**", and together with its subsidiaries "**BioSenic Group**") prepared the present supplement (the "**Supplement**"), which is supplemental to BioSenic's registration document as approved by the Belgian Financial Services and Markets Authority (*Autorité des services et marchés financiers*, the "**FSMA**") on 7 February 2023 (the "**Registration Document**"), in relation to:

(i) the prospectus dated 7 February 2023 regarding the admission to trading of up to 115,132,015 new shares and 24,463,421 subscription rights on Euronext Brussels and Euronext Paris; and

(ii) the prospectus dated 6 November 2023 regarding the admission to listing and trading on Euronext Brussels and Euronext Paris of (i) 8,202,989 new shares of the Company issued on 25 September 2023 as part of the conversion of 10 Convertible Bonds in accordance with the terms and conditions of a subscription agreement dated 30 May 2022 between the Company and Global Tech Opportunities 15 ("**GTO 15**"), as amended (the "**Subscription Agreement**") and (ii) up to 109,250,000 new shares of the Company (together with the 8,202,989 new shares, the "**New Shares**") that may be issued by the Company upon conversion of a maximum of 40 Convertible Bonds and EUR 185,000 in new convertible bonds issued and/or to be issued under the Subscription Agreement (as amended).

In order to ensure that the information contained in the Registration Document is up-to-date – as required by the Regulation (EU) 2017/1129 (the "**Prospectus Regulation**") – the Registration Document is deemed to be amended as set out below.

The English version of the Supplement was approved by the FSMA on 6 November 2023 in its capacity as competent authority under the Prospectus Regulation. The FSMA's approval does not imply any judgment on the situation of the Company. The FSMA only approves the Supplement as meeting the standards of completeness, comprehensibility and consistency imposed by Prospectus Regulation. Such approval should not be considered as an endorsement of the quality of the New Shares.

The Supplement has been translated into French. The Company is responsible for the consistency between the French and English versions of the Supplement. Without prejudice to the responsibility of the Company for the inconsistencies between the different language versions of the Supplement, in the case of discrepancies between the different versions of these supplements the English version will prevail. The Supplement will be published on the website of the Company (https://biosenic.com/) and will also be made available to investors, at no cost, at the Company's registered office. Following its approval, the Supplement, together with a French translation, will be notified by the FSMA to the AMF in France in accordance with the Prospectus Regulation, which does not imply any judgement by the AMF on the merits or the quality of the Company or the Shares.

Save as disclosed in the Supplement, there has been no other significant new factor, material, mistake or inaccuracy since the date of publication of the Registration Document.

The Board of Directors of BioSenic SA assumes responsibility for the content of the Supplement. The Board of Directors declares that the information contained in this Supplement, is to the best of its knowledge, in accordance with the facts and makes no omission likely to affect its import.

On behalf of the Board of Directors,

Prof. François Rieger
President of the Board of Directors and CEO

Véronique Pomi-Schneiter
Director and Deputy CEO

<u>This section replaces Section 1.6 "Risk factors linked to intellectual property:</u>

a. BioSenic Group's patents and other intellectual property rights portfolio may not adequately protect its research programmes and other product candidates, or BioSenic Group may not be able to protect and/or enforce its intellectual property rights in all key countries or territories, which may impede BioSenic Group's ability to compete effectively

BioSenic Group's success will depend in part on its ability to obtain, maintain and enforce its patents and other intellectual property rights. BioSenic Group's research programmes and product candidates are covered by several patent application families, which are either licensed to BioSenic Group or owned by the Group. For more information about BioSenic Group's patents and patent applications (please see Section 4.17 of this Registration Document for further details). Currently, BioSenic Group manages:

- 8 patent families related to the ALLOB technology (including one patent family owned and exclusively licensed by the ULB) with expiry dates comprised between 2027 and 2039;
- 5 patent families related to the JTA technology (including three patent family co-owned with Glob-Co) with expiry dates comprised between 2029 and 2043;
- 4 patent families related to the medical use of arsenic salts alone or in combination with metal ions (Arscicop and Arscimed) with expiry dates comprised between 2038 and 2043;
- two patent families licensed to Medenic by Phebra related to oral formulations of arsenic trioxide (Arscicor / OATO), their preparation, and their use for treating various immunopathologies when commercially exploited in specified territories, with expiry dates comprised between 2036 and 2037;
- one patent family covering the use of the IV formulation ATO for treating specific autoimmune and inflammatory diseases (licensed from CNRS) with expiry dates comprised between 2030 and 2031 (in USA only; already expired in other jurisdictions).

Although BioSenic Group can still benefit from its developed know-how, once patent protection is lost this could force BioSenic Group to license or develop new formulations of ATO. The advantage of BioSenic Group's changed focus on OATO (instead of IV formulation) – in additional to the treatment advantages of OATO as further described in this Registration Document – allows it to benefit from the additional patent protection on OATO and to minimise the impact of the recent expiry in 2023 of CNRS' European patent relating to the IV formulation. In addition, the loss of patent protection could negatively affect the revenues of BioSenic Group from the relevant products as competitors might want to take advantage of the expiration of patent protection.

BioSenic Group may not be able to obtain or maintain these patent rights against patent offices and other third-party challenges to their validity, scope and or enforceability. BioSenic Group may not be (or have been) the first to conceive an invention and to file a patent or a patent application. Because patent law in the biopharmaceutical industry is highly uncertain, there can be no assurance that the technologies used in BioSenic Group's research programmes and product candidates are patentable, that patents will be granted to BioSenic Group or its licensors under pending or future applications, or that patents will be of sufficient breadth to provide adequate and commercially meaningful protection against competitors with similar technologies or products, or that patents granted to BioSenic Group or its licensors will not be successfully challenged, circumvented, invalidated or rendered unenforceable by third parties, hence enabling competitors to circumvent or use them and depriving BioSenic Group of the protection it may expect against competitors. Moreover, it cannot be excluded for the ALLOB product that the debate on the patentability of elements of the human body could lead to a situation whereby the technology developed by or licensed to BioSenic Group can no longer be protected by patents or that such patents cannot be enforced against third parties. A third party's ability to use unpatented technologies is enhanced by the fact that the published patent application contains a detailed description of the relevant technology. Third parties might claim ownership rights over the patents

or other intellectual property rights owned or held by BioSenic Group. To date, no invalidation or opposition process has been made against the patent portfolio of BioSenic Group.

Several of BioSenic Group's patents are already granted in Europe, US, Japan, Australia, Canada, China, Hong Kong, Israel, India, South Korea and Singapore, depending on the patent family considered. The current prosecution of its or its licensors' patent applications may not result in granted patents in each of the territories. Filing, prosecuting and defending their patents throughout the world would be prohibitively expensive for BioSenic Group and its licensors. Competitors may use BioSenic Group's technologies in jurisdictions where BioSenic Group or its licensors have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where BioSenic Group has patent protection but where enforcement is not as well developed as in the United States or the European Union. These products may compete with BioSenic Group's products in jurisdictions where BioSenic Group or its licensors do not have any issued patents and BioSenic Group's patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing. Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favour the enforcement of patents and other intellectual property rights, particularly those relating to biopharmaceuticals, which could make it difficult for BioSenic Group to stop the infringement of its patents or marketing of competing products in contravention of its proprietary rights generally. The inability of BioSenic Group to protect and/or enforce some of its intellectual property rights in the selected territories in which it seeks patent protection could have a material adverse effect on the Group's ability to maximise the market potential of its product candidates, which would result in severe adverse effect on its business, prospects, financial conditions, and results of operations.

Moreover, periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid by BioSenic Group and/or its licensors to the relevant patent agencies in several stages over the lifetime of the licensed patents and/or applications. The relevant patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In many cases, an inadvertent lapse may be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance may result in abandonment or lapse of the patent or patent application, resulting in a partial or complete loss of patent rights in the relevant jurisdiction. In such an event, BioSenic Group 's competitors might be able to use its technologies and those technologies licensed to BioSenic Group and this circumstance would have an adverse effect on its business, prospects, financial conditions, and results of operations.

b. Should BioSenic Group be unable to obtain new license rights on reasonable terms, or if it would lose any of its licenses or otherwise experiences disruptions to its business relationship with its licensors, BioSenic Group might be unable to develop, manufacture or sell its products

BioSenic Group's activities are dependent – at least in part – on the use of intellectual property rights which are for some projects not owned by it, but have been given exclusive access pursuant to license agreements and which are important to the business.

BioSenic Group is currently renegotiating the scope and commercial terms of (i) the license agreement and (ii) the marketing and supply agreement entered into between Medsenic and Phebra respectively on 21 and 31 May 2021. Under these agreements, Phebra has granted an exclusive license to Medsenic to use the oral formulation of arsenic trioxide for its research and clinical development in various immunopathologies and to market and distribute the product in such field in the European Union, Switzerland, and in other non-European countries (defined as "**Medsenic Territories**" in the agreement). Phebra agreed to provide a free clinical supply (either directly or via a contract manufacturer) of up to an equivalent of EUR 200,000 of the oral formulation of arsenic trioxide for Medsenic's indication at the start of the Phase III clinical trial, which should allow BioSenic Group to cover approximately the first 12 months of the trial. In consideration for the license granted for the Medsenic Territories, Phebra received 3,151 shares (4.3% of the shares currently outstanding)

in Medsenic. Phebra retains the right to commercialise the product in all countries outside the Medsenic Territories against payment to Medsenic of a royalty of 55% of the net sales profits. BioSenic Group and Phebra are now currently analysing the possibility to extend the Medsenic Territories and the commercial terms thereof, which is expected to require lengthy and complex discussions and agreements based on partially unknown commercial and competitive factors. A letter of intent and non-binding term sheet are being prepared. As a result, there is a clear risk that BioSenic Group might not obtain the right to commercialise the oral formulation of arsenic trioxide in key jurisdictions (including the USA, Japan and UK) or acquire such rights on commercially unfavourable terms, specifically in relation to the definition of milestones and corresponding payments to be made by BioSenic Group to Phebra. This could substantially impair BioSenic Group's ability to generate sufficient future revenues from its existing clinical programmes, which would have an adverse impact on its valuation and possibility its ability to raise additional funding thereby threatening BioSenic Group's ability to continue as a going concern.

Under the license agreement with Phebra, Medsenic had agreed to commence a clinical study using Phebra OATO before 31 May 2023. If such study would not start before 31 May 2023, Phebra could terminate the license agreement unless the parties agree to postpone such date. On 29 May 2023, BioSenic announced the amendment of the license agreement with Phebra. The license agreement grant is now subject to Medsenic's ability to commence a clinical study using OATO before 31 May 2024.

BioSenic Group has also a dependence on the license agreement entered into by Medsenic with CNRS regarding the patent family owned by the CNRS that claims the use of arsenic salts for autoimmune indications patent. We refer to Section 4.12.2.1 (License agreement with the Centre National de la Recherche Scientifique (CNRS) in France) for further information in that regard. The patents licensed from the CNRS relate to the use of arsenic salts generally to treat autoimmune diseases. As the patents of the CNRS covering the European Union and the U.S. expire, respectively, in 2023 and 2029, BioSenic Group is dependent on the development of new formulations of ATO (such OATO as licensed from Phebra or a combination of matter such as ArsciCop) to be able to obtain additional patent protection for its clinical assets. As BioSenic Group is indeed focussing its clinical development on the oral formulation of ATO (for which patent protection is available until 2036) and given that it has received orphan drug designation for the treatment of GvHD with ATO from EMA and FDA (which gives market exclusivity of, respectively, 7 and 10 years in the US and Europe once the medicine is approved for commercialisation), the risk related to the expiry of the aforementioned CNRS patent in the European Union is considered to be low.

For its clinical programmes BioSenic Group has also entered into license agreements with third parties regarding the ULB-028 patent family. Also, BioSenic Group has been granted exclusive worldwide rights from Glob-Co SRL to develop, manufacture, sublicense and sell any products of the JTA technology for human application.

The conditions under which BioSenic Group may acquire future rights or maintain the rights granted to it include, but are not limited to, the payment of (i) fees upon achievement of certain milestones, (ii) royalties on the (net) sales of relevant licensed products, (iii) a percentage of revenues incurred from sub-licensees, as well as the performance of other obligations, such as compliance with research and development obligations and with marketing and distribution arrangements. Furthermore, delays or interruptions in the development or exploitation of the relevant technology may be sanctioned under the terms and conditions of the license agreements. If BioSenic Group fails to comply with its obligations under the respective license agreements, licensors may reduce the scope of the license or terminate the license, resulting in the loss of the use of the related intellectual property rights. Should BioSenic Group be unable to obtain new rights on reasonable terms similar to those which it holds under such license, or if it would lose any of its licenses, BioSenic Group might be unable to develop, manufacture or sell its products or should be obliged to develop new innovative products, with important delayed access to the desired market. This could have adverse effects on BioSenic Group's business, prospects, financial conditions, and operational results for a longer period.

c. If BioSenic Group is not able to prevent disclosure of its trade secrets, know-how, (non)biological materials, or other proprietary information, the value of its technology and product candidates could be significantly diminished.

BioSenic Group relies on trade secret protection to protect its interests in its know-how, (non-)biological materials, or other proprietary information and processes for which patents are difficult to obtain or enforce, all of which constitute confidential information. BioSenic Group may not be able to protect its confidential information adequately. BioSenic Group has a policy of requiring its consultants, contract personnel, advisers and third-party partners to enter into confidentiality agreements. However, there is no assurance that such agreements will provide for the meaningful protection of confidential information in the event of any unauthorised use or disclosure of information and that any of BioSenic Group employees, consultants, contract personnel or third-party partners, either accidentally or through wilful misconduct, will not cause serious damage to its programmes and/or its strategy, by, for example, disclosing confidential information to its competitors. It is also possible that confidential information could be obtained by third parties as a result of breaches of physical or electronic security systems of BioSenic Group, its consultants, advisers, third-party partners or other parties that have had access to its confidential information. Any disclosure of confidential data into the public domain or to third parties could allow BioSenic Group's competitors to learn confidential information and use it in competition against BioSenic Group. In addition, others may independently discover BioSenic Group's confidential information. Any action to enforce BioSenic Group's rights against any misappropriation or unauthorised use and/or disclosure of confidential information is likely to be time-consuming and expensive, and may ultimately be unsuccessful, or may result in a remedy that is not commercially valuable.

d. BioSenic Group may infringe on the patents or intellectual property rights of others and mayface patent litigation, which may be costly and time consuming and could result in BioSenic Group having to pay substantial damages or limit BioSenic Group's ability to commercialise its product candidates.

BioSenic Group's success will depend in part on its ability to operate without infringing on or misappropriating the intellectual property rights of others. BioSenic Group's activities, or those of its licensors, might infringe on the patents or other intellectual property rights owned by others. BioSenic Group may expend significant time and efforts and may incur substantial costs in litigation if it is required to defend patent or other intellectual property right claims brought against BioSenic Group or its licensors regardless of whether the claims have any merit. Additionally, BioSenic Group cannot predict whether it or its licensors will be successful in any litigation. If BioSenic Group or its licensors are found to have infringed the patents or other intellectual property rights of others, it may be subject to substantial claims for damages, which could materially impact BioSenic Group 's cash flow and financial position. BioSenic Group may also be required to cease development, use or sale of the relevant research programme, product candidate or process or it may be required to obtain a license for the disputed rights, which may not be available on commercially reasonable terms, if at all. BioSenic Group may be unable to develop or commercialise a product, product candidate or research programme, or may cease some of its operations, which may have an adverse effect on BioSenic's business, prospects, financial conditions, and results of operations.

To date, no patent infringement claim has been made against the BioSenic Group but, in such a situation, BioSenic Group will evaluate legal opportunities and provisions that may allow limiting or invalidating the claims in patents owned by others being allegedly infringed by BioSenic Group in a given country and/or for any specific commercial, development, research, or manufacturing activity.

e. BioSenic co-owns the JTA patent families together with Enrico Bastianelli SRL and is discussing the opportunity to enter into new co-ownership rules for the JTA patent families. It is, however, uncertain that parties will reach an agreement, the absence of which could give rise to co-ownership and exploitation problems for the use of the JTA technology and could therefore have a negative impact on BioSenic's possibilities to collaborate with external partners for the future development of the JTA technology.

BioSenic co-owns the JTA patent families – being BPBONE-001, BPBONE-002 and BONE-011 patent families – alongside Enrico Bastianelli SRL (previously Glob-Co SRL). Enrico Bastianelli SRL, with registered office is in Jumet, Belgium, is controlled by Mr Enrico Bastianelli.

In 2020, BioSenic entered into a license and co-ownership agreement with Glob-Co SRL regarding the JTA patent families BPBONE-001, BONE-002, BONE-011 and any future patents related to the JTA technology. This agreement provided to BioSenic an exclusive, worldwide and sublicensable right to use the co-owned patent families for all human applications. This agreement further provided to Glob-Co SRL an exclusive, worldwide and sublicensable right to use the same co-owned patent families for all veterinary applications.

Following disappointing Phase III clinical results, Biosenic transferred its rights to the JTA technology to the Walloon Region and consequently terminated the license agreement with Glob-Co SRL in 2022. In March 2023, however, BioSenic obtained new statistical analysis results from the JTA-004 Phase III clinical trial data. This new post-hoc analysis changes the therapeutic profile of the molecule and potentially allows for the possibility of stratifying patients for a new, optimized Phase III clinical study. The agreement with respect to the to JTA technology (including intellectual property rights forming the JTA-Gen1 patent families) has been since reacquired from the Walloon Region, as the Walloon Region accepted to retrocede its rights to the JTA technology to BioSenic Group in 2023. BioSenic is still discussing the opportunity with Enrico Bastianelli SRL to enter into new co-ownership rules for the JTA-Gen1 patent families, the absence of which could give rise to exploitation problems for the use of the JTA technology and could therefore have a negative impact on BioSenic's possibilities to collaborate with external partners for the future development of the JTA technology.

This section replaces Section 3.1 "Information incorporated by reference" of the Registration Document:

This Registration Document shall be read and construed in conjunction with the following documents:

(i) the annual report and audited consolidated financial statements of BioSenic prepared in accordance with IFRS for the financial year ended 31 December 2020 (in English and French), together with the related audit report thereon (available via the following hyperlinks https://biosenic.com/sites/default/files/2022-09/AR_2020_Full_EN_final.pdf; https://www.biosenic.com/sites/default/files/2022-09/AR_2020_Full_FR_final.pdf);

(ii) the annual report and audited consolidated financial statements of BioSenic prepared in accordance with IFRS for the financial year ended 31 December 2021 (in English and French), together with the related audit report thereon (available via the following hyperlinks https://biosenic.com/sites/default/files/2022-09/BOTHE_AR2021_EN_vFinal.pdf; https://www.biosenic.com/sites/default/files/2022-09/BOTHE_AR2021_FR_vFinal.pdf;

(iii) the annual report and audited consolidated financial statements of BioSenic prepared in accordance with IFRS for the financial year ended 31 December 2022 (in English and French), together with the related audit report thereon (available via the following hyperlinks https://www.biosenic.com/node/645; https://www.biosenic.com/fr/node/646);

(iv) the condensed consolidated unaudited interim financial statements of BioSenic prepared in accordance with IFRS for the financial period ended 30 June 2023 (in English and French) (available via the following hyperlinks https://biosenic.com/sites/default/files/2023-09/BIOS_Report_H1Y23_EN_Final_0.pdf).

Copies of documents incorporated by reference in this Registration Document may be obtained (without charge) from the registered offices of BioSenic and the website of BioSenic (https://biosenic.com/investors). BioSenic confirms that it has obtained the approval from its auditors to incorporate in this Registration Document the audited consolidated financial statements and the auditors' reports thereon for the financial years ended 31 December 2020, 31 December 2021 and 31 December 2022.

The tables below include references to the relevant pages of the audited consolidated financial statements of BioSenic for the financial years ended 31 December 2020, 31 December 2021 and 31 December 2022, as set out in the annual reports of BioSenic (in English and French), as well as the unaudited condensed consolidated interim financial statements for the financial period ended 30 June 2023. Information contained in the documents incorporated by reference other than information listed in the tables below is either not relevant for the investor or covered elsewhere in the Registration Document.

Audited consolidated financial statements of BioSenic prepared in accordance with IFRS for the financial period ended 31 December 2020, as set out in the annual report (in English and French).	
Business overview	p. 12-17
Financial review of the year ending 31 December 2020	p. 20-24
Consolidated statement of financial position	p. 80
Consolidated statement of comprehensive income	p. 81
Consolidated statement of cash flows	p. 82
Consolidated statement of changes in equity	p. 83
Notes to the consolidated financial statements	p. 84-123
Auditor' s report	p. 73-79

Audited consolidated financial statements of BioSenic prepared in accordance with IFRS for the financial period ended 31 December 2021, as set out in the annual report (in English and French).	
Clinical and Operational review 2021	p. 14
Financial review of the year ending 31 December 2021	p. 16-22
Consolidated statement of financial position	p. 79
Consolidated statement of comprehensive income	p. 80
Consolidated statement of cash flows	p. 81
Consolidated statement of changes in equity	p. 82
Notes to the consolidated financial statements	p. 83-122
Auditor' s report	p. 72-78

Audited consolidated financial statements of BioSenic prepared in accordance with IFRS for the financial period ended 31 December 2022, as set out in the annual report (in English and French).	
Business overview	p. 10-19
Financial review of the year ending 31 December 2022	p. 20-25
Board of Directors	p. 33-42
Executive Committee	p. 42-45
Remuneration report	p.50-59
Consolidated statement of financial position	p. 87
Consolidated statement of comprehensive income	p. 88
Consolidated statement of cash flows	p. 89
Consolidated statement of changes in equity	p. 90
Notes to the consolidated financial statements	p. 91-135
Auditor' s report	p. 80-86

Condensed consolidated unaudited interim financial statements of BioSenic prepared in accordance with IFRS for the financial period ended 30 June 2023, as set out in the interim report (in English and French).	
Condensed consolidated statement of financial position	p. 6
Condensed consolidated statement of comprehensive income	p. 7
Condensed consolidated statement of changes in equity	p. 8

This section replaces Section 3.7 "Significant change in the financial position of the BioSenic Group since 31 December 2021" of the Registration Document:

Section 3.7 Significant change in the financial position of the BioSenic Group since 31 December 2022

On 21 February 2023, BioSenic announced it received EUR 1 million (minus 6% taxes) from Pregene in accordance with the terminated license agreement.

From 1 January 2023 until 30 September 2023, a total of EUR 1.5 million of Convertible Bonds was converted into shares for a total of 41,283,728 shares. Following the conversions, the total of shares as of 30 September 2023 amounted to 163,181,474 shares.

In June 2023, BioSenic entered into an agreement with the ABO Securities subsidiary, Global Tech Opportunities 15, to secure short term financing based on the existing convertible bond program. Subject to the terms and conditions of the agreement, BioSenic shall be entitled to draw down three tranches of each EUR 0.3 million in June, July, and August under the existing convertible bond program, for an aggregate principal amount of EUR 0.9 million.

In July 2023, BioSenic has achieved a standstill agreement from the main historical creditors for a period of 3 to 4 months. Given this agreement with the main creditors and the one obtained on 30 June 2023 with Global Tech Opportunities 15 to secure short-term financing based on the existing convertible bond program, BioSenic anticipates having sufficient cash to carry out its business objectives until October 2023.

During the first six months of 2023, total operating income amounted to EUR 0.37 million, a slight increase compared to the same period in 2022 (EUR 0.13 million).

Operating loss for the period amounted to EUR 3.90 million, compared to EUR 0.48 million in H1 2022.

BioSenic ended the first six months of 2023 with EUR 0.52 million in cash and cash equivalents. Net cash used for the period amounted to EUR 1.33 million, compared to EUR 0.39 million over the same period of 2022.

On 14 September 2023, BioSenic announced that it has reached an agreement with Patronale, Monument and the European Investment Bank for the restructuring of its key financial debts for an aggregate outstanding principal amount of EUR 15.5 million plus accrued interests. The in principle agreement of the European Investment Bank remains subject to its internal credit approval. The agreements that the Company reached with Patronale, Monument and the European Investment Bank for the restructuring of its key financial debts are conditional upon BioSenic raising sufficient new equity to continue its operations including the initiation of the patient treatment in Q2 2024 of a Phase 3 clinical trial of its lead Oral ATO therapeutic candidate targeting cGvHD.

On 18 October 2023, BioSenic announced that it has reached a definitive agreement with GTO 15 with respect to the finalization of the existing convertible bonds program. GTO 15 will fund two tranches of EUR 300,000 each of the existing convertible bonds program. The EUR 600,000 will be drawn in two successive tranches of EUR 300,000.

This section replaces Section 3.8 "Current cash situation" of the Registration Document:

BioSenic Group does currently not have sufficient working capital to meet its present requirements and cover the working capital needs for a period of at least 12 months as of the date of this Supplement.

BioSenic ended the first six months of 2023 with EUR 0.52 million in cash and cash equivalent. The Company is in the process of closing the ALLOB Phase IIb clinical trial, with many actions to be carried out to follow up the last patients recruited at the end of last year and the beginning of 2023, as well as the regulatory closure of the 24 European centers involved. BioSenic anticipates having sufficient cash to launch Phase 3 clinical trials in cGvHD, considering the following relevant assumptions:

- Finalisation and implementation of the key terms that were agreed with certain key historical creditors of the Company to postpone the maturity date and interest payments of the ongoing loans for an aggregate principal amount of EUR 15.5 million.
- A successful fundraising or the negotiation of a renewed convertible bond program.
- A reinforced strict policy of cost management.

The assumptions made above comprise various risks and uncertainties.

As the cash runway of the Company is currently expected into January 2024, BioSenic Group will continue to require additional financing to continue its operations in the longer turn. If BioSenic Group would not satisfy the conditions under the Convertible Bonds facility with GTO 15 to draw down the final tranche of €300,000 in November 2023, BioSenic will run out of cash by mid-December 2023. Even if the above assumptions are realized, BioSenic will require additional financing to continue its operations after end of January 2024. The shortfall over the 12-month period from the date of approval of the Securities Note is estimated at approximately EUR 10 million. BioSenic Group therefore continues to evaluate other options with a potential positive impact on going concern, including as follows:

- *Fundraising*. BioSenic is currently preparing a fundraising to be organized in Q4 2023. Securing this fundraising will be a condition to a successful deal with the main creditors. BioSenic Group expects for 2024 to use the proceeds of anticipated future fundraisings in priority for progressing the Phase 3 clinical trial in cGvHD. As a result, it will only be possible to start the SLE and SSc Phase IIb clinical trials if the BioSenic Group succeeds in concluding a strong partnership with a biopharmaceutical company or if it manages to successfully out-license some of its technology. The start of SLE and SSc Phase 2 clinical trials is therefore not envisioned before 2024.
- *Potential partnership to develop and commercialize of JTA*. BioSenic, which does not intend to allocate R&D resources to support the clinical development of JTA-004, is seeking to collaborate with existing and potential partners to explore options for the future development of JTA-004 based on this new post-hoc analysis. Following disappointing Phase 3 clinical results, Biosenic transferred its rights to the JTA technology to the Walloon Region and consequently terminated the license agreement with Glob-Co SRL in 2022. In March 2023, however, BioSenic obtained new statistical analysis results from the JTA-004 Phase III clinical trial data. This new post-hoc analysis changes the therapeutic profile of the molecule and potentially allows for the possibility of stratifying patients for a new, optimized Phase III clinical study. The agreement with respect to the to JTA technology (including intellectual property rights forming the JTA-Gen1 patent families) has been since reacquired from the Walloon Region, as the Walloon Region accepted to retrocede its rights to the JTA technology to BioSenic Group in 2023. BioSenic is still discussing the opportunity with Glob-Co SRL to enter into new co-ownership rules for the JTA-Gen1 patent families, the absence of which could give rise to exploitation problems with for the use of the JTA technology and could therefore have a negative impact on BioSenic's possibilities to collaborate with external partners for the future development of the JTA technology.
- *Potential partnership to develop and commercialize of ALLOB*. In October 2022, BioSenic regained worldwide rights to develop, manufacture and commercialised ALLOB following the termination by Shenzhen Pregene Biopharma Co., Ltd ("**Pregene**") of the exclusive license agreement entered into between BioSenic, Pregene and Link Health Pharma Co., Ltd ("**LinkHealth**") in October 2020. Following the recovery of the worldwide rights to ALLOB, BioSenic received a final payment of € 1.00 million from Pregene linked to the achievement of a development milestone. Although regulatory changes in China have halted establishment of ALLOB in the Chinese market, BioSenic continues preliminary discussions with Pregene, LinkHealth and other potential partners to reach an agreement for the development and commercialization of ALLOB in other geographies, including in the U.S., based on the information collected by BioSenic's past preclinical research as well as the present review and work on the clinical trials performed.

This section replaces Section 4.1 "Important recent events in the development of BioSenic Group's business" of the Registration Document:

Key Milestones of BioSenic	
YEAR 2023	
Corporate	• Appointment of Dr Carole Nicco as Chief Scientific Officer. • Appointment of Mr Yves Sagot as Independent Director. • BioSenic received EUR 1 million (minus 6% taxes) Pregene as a settlement following the termination by Pregene of the exclusive license agreement entered into between BioSenic, Pregene and Link Health Pharma. • Appointment of Lieven Huysse, MD as Chief Medical Officer. • Agreement with Patronale, Monument and the European Investment Bank for the restructuring of BioSenic's key financial debts.
ALLOB	• Optimization of ongoing Phase IIb clinical trial ALLOB and completion of patient recruitment. • BioSenic and Pluristyx sign term sheet for market availability of ALLOB mesenchymal cells. • BioSenic puts Phase IIb ALLOB trial on hold following negative results obtained for the primary endpoint.
JTA	• Re-evaluation of the results of its Phase III trial of JTA-004 targeting knee osteoarthritis in the subset of patients with the most painful and inflammatory form of knee osteoarthritis shows a pain-relieving effect of JTA-004 not only superior to placebo but also to the active comparator. • BioSenic reacquires intellectual property rights to JTA-004 from the Walloon region.
Immune diseases	• Publication of data providing additional details about the mechanism of action of its lead API arsenic trioxide (ATO) to prevent autoimmune diseases published in the peer-reviewed paper *Frontiers in Immunology*[1]. • BioSenic received a key European patent from EPO, for further therapeutic development in cancer, infectious and immune disease covering the therapeutic use of a new composite formulation of anti-inflammatory compounds with unique advantages. • BioSenic identifies key biomarkers for cGvHD and submits patent to EPO. • Amendment of the license agreement between Medsenic SAS and Phebra Pty Ltd to extend the deadline for the launch of the phase 3 clinical trial of OATO for the treatment of cGvHD from 31 May 2023 to 31 May 2024. • BioSenic received a Chinese patent protecting the combined use of metal ions and arsenic salts to treat a wide range of serious diseases. • Publication of data providing additional key indications of arsenic trioxide (ATO) to treat systemic sclerosis (SSc) in a peer-reviewed international journal. • BioSenic completed a post-hoc analysis of its phase 2 clinical trial of ATO, finding the best scheme for administration of oral arsenic trioxide for an efficient treatment of cGvHD.
YEAR 2022	
Corporate	• BioSenic secures a € 5 million convertible bonds facility with ABO. • Contribution of 51% of the shares of Medsenic in exchange for the issuance of 90,668,594 new shares of BioSenic.

[1] Charlotte Chêne, Dominique Rongvaux-Gaïda, Marine Thomas, François Rieger, Carole Nicco, Frédéric Batteux "Optimal combination of arsenic trioxide and copper ions to prevent autoimmunity in a murine HOCl-induced model of systemic sclerosis", in Front. Immunol., 30 March 2023, Volume 14. Link: https://www.frontiersin.org/articles/10.3389/fimmu.2023.1149869/full.

	• BioSenic regains worldwide rights to its allogeneic, off-the-shelf, bone cell therapy platform ALLOB further to the unilateral termination notice received from Shenzhen Pregene Biopharma Co., Ltd.
ALLOB	• BioSenic announced an optimized statistical analysis plan and the implementation of an interim analysis for the ongoing Phase IIb clinical trial with its allogeneic bone cell therapy product, ALLOB.
JTA	• BioSenic redefines its strategic priorities to concentrate specifically on the development of its most advanced clinical asset, the allogeneic cell therapy platform, ALLOB.
cGvHD	• Medsenic Receives Positive Pre-IND Response from FDA to Initiate a Phase III Clinical Study in cGvHD. • Medsenic publishes its positive Phase II results in an international journal, Transplantation and Cellular Therapy, May 2022[2].

This section replaces Section 4.6 "Current clinical pipeline and outlook" of the Registration Document:

Currently BioSenic Group is concentrating specifically on the development the preparation of a Phase III clinical trial for the use of oral arsenic trioxide for the treatment of cGvHD, which is expected to take approximately 4 years to complete the last patient visit.

See the summary timeline below for more details on these two clinical assets.



BioSenic's subsidiary Medsenic has completed the set-up of the technical conditions (regulatory, CRO designation and clinical centers identification) for the Phase III clinical trial for the use of oral arsenic trioxide to treat cGvHD. It is currently expected that the CRO will be formally engaged end 2023 and the first recruited patient will be treated in Q2 2024, subject to BioSenic finding additional equity or debt financing for the start of the clinical trial.

[2] Dominique Rongvaux-Gaïda, Maëva Dupuis, Joël Poupon, Nouzha Djebrani-Oussedik, Catherine Lemonnier, François Rieger. "High Response Rate and Corticosteroid Sparing with Arsenic Trioxide-Based First-Line Therapy in Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation", in Transplantation and Cellular Therapy, Volume 28, Issue 10, October 2022, Pages 679.e1-679.e11. Abstract.

Future Pipeline Development



BioSenic Group will continue to prepare for the start of its Phase III for the use of oral arsenic trioxide for cGvHD. It is currently expected that the CRO will be formally engaged end 2023 and the first recruited patient will be treated in Q2 2024, subject to BioSenic finding additional equity or debt financing for the start of the clinical trial.

In parallel, BioSenic Group will search for partnerships with interested biopharmaceutical companies for performing the two Phase II clinical trials, randomized, on top of standard care, against placebo for SLE and SSc. BioSenic Group expects to use the existing cash and the proceeds of anticipated future fundraisings (via shares or (convertible) bonds) in priority for progressing the Phase III clinical trial in cGvHD. As a result, it will only be possible to start the SLE and SSc Phase II clinical trials if the BioSenic Group succeeds in concluding a strong partnership with a biopharmaceutical company or if it manages to successfully out-license some of its technology. The start of SLE and SSc Phase II clinical trials is therefore not envisioned before end of 2024.

Outlook for the remainder of 2023

In October 2022, BioSenic regained worldwide rights to develop, manufacture and commercialised ALLOB following the termination by Shenzhen Pregene Biopharma Co., Ltd ("**Pregene**") of the exclusive license agreement entered into between BioSenic, Pregene and Link Health Pharma Co., Ltd ("**LinkHealth**") in October 2020. Although regulatory changes in China have halted establishment of ALLOB in the Chinese market, BioSenic has started preliminary discussions with Pregene, LinkHealth and other potential partners to reach an agreement for the development and commercialization of ALLOB in other geographies, including in the U.S., based on the information collected by BioSenic's past preclinical research as well as the present review and work on the clinical trials performed.

In March 2023, BioSenic has obtained new statistical analysis results from the JTA-004 Phase III clinical trial data. This new post-hoc analysis changes the therapeutic profile of the molecule and potentially allows for the possibility of stratifying patients for a new, optimized Phase III clinical study. BioSenic, which does not intend to allocate R&D resources to support the clinical development of JTA-004, is seeking to collaborate with existing and potential partners to explore options for the future development of JTA-004 based on this new post-hoc analysis. However, following disappointing Phase III clinical results, Biosenic terminated the license and co-ownership agreement and transferred its rights to the JTA-004 technology to the Walloon Region in 2022. The agreement with respect to the JTA-004 patent and technology has been since reacquired from the Walloon Region, as the Walloon Region accepted to retrocede its rights to the JTA-004 technology to BioSenic in 2023. BioSenic is still discussing the opportunity with Glob-Co SRL to enter into new co-ownership rules for the JTA-

004 patent, the absence of which could give rise to co-ownership and exploitation problems with for the use of the JTA-004 patent.

The Medsenic Phase II clinical study with arsenic trioxide in the first-line treatment of cGvHD is complete and provided positive results. A Phase III study with oral arsenic trioxide in the first-line treatment of cGvHD, for which Medsenic received positive pre-IND response from the FDA, is currently anticipated to start in 2024. A phase IIa clinical trial for systemic lupus erythematosus ("**SLE**") had previously established safety for the patient and efficacy on the course of the autoimmune disease. Positive preclinical work gives good grounds for a Phase II clinical trial on systemic sclerosis ("**SSc**"). Phase IIb clinical trials for SLE and SSc are in the planning stage with the protocols for both studies being ready.

BioSenic is currently preparing a fundraising to be organized in Q4 2023. BioSenic Group expects for 2024 to use the proceeds of anticipated future fundraisings in priority for progressing the Phase III clinical trial with arsenic trioxide (ATO) to treat chronic graft versus host disease (cGvHD), for which patient treatment is currently scheduled to start in Q2 2024. As a result, it will only be possible to start the SLE and SSc Phase IIb clinical trials if the BioSenic Group succeeds in concluding a strong partnership with a biopharmaceutical company or if it manages to successfully out-license some of its technology. The start of SLE and SSc Phase II clinical trials is therefore not envisioned before the end of 2024.

Disciplined cost and cash management will remain a key priority. The situation will be actively and closely monitored.

This section replaces Section 4.10.1 "Delayed-union fractures", penultimate and ultimate paragraph of the Registration Document:

In February 2023, BioSenic announced an optimization of the study and patient recruitment completion. BioSenic has utilized scientific advances and market knowledge in feature healing and scientific advances in radiology to initiate positive modifications to its trial. As a result, the study has advanced from seeking pure basic clinical assessments to involving more quantitative data. This has allowed for a superior significance analysis. This advance in the trial results assessment has been achieved through advances in radiographic procedures enabling increased clarity in statistical interpretation. As a result, BioSenic has decided, based on consultation with its external biostatistical advisors, that clinical investigators may stop the recruitment of patients. The cohort of treated patients, amounting to 57 patients, is found to be sufficient for a sufficient level of significance.

On 19 June 2023, BioSenic announced putting the Phase IIb ALLOB trial on hold following negative results obtained for the primary endpoint. The Company is currently in the process of closing the ALLOB Phase IIb clinical trial, with many actions to be carried out to follow up the last patients recruited at the end of last year and the beginning of 2023, as well as the regulatory closure of the 24 European centres involved.

This section replaces Section 4.10.3 "JTA-004 (discontinued)", three last paragraphs of the Registration Document:

In August 2021, BioSenic announced the primary results of its Phase III study evaluating the potential of a single intra-articular injection of JTA-004 for the reduction of osteoarthritis pain in the knee for up to 12 months, compared to placebo or Hylan G-F 20, the current market-leading osteoarthritis treatment. The Phase III study was a randomized, double-blind, controlled trial conducted at 22 centers in six European countries and in the Hong Kong SAR. Over 700 patients were treated. JTA-004 had an excellent safety profile. However, the study did not meet its primary or secondary endpoints. No statistically significant difference in pain reduction between the treatment, placebo or comparative groups could be observed, with all treatment arms showing similar efficacy.

In March 2023, BioSenic announced that it has used the statistical analysis capabilities of Artialis to re-evaluate the results of the Phase III JTA-004 trial in the subset of patients with the most painful and inflammatory form of knee osteoarthritis (OA). This allowed BioSenic to distinguish a group of patients, representing about one third of the total patients, who show a pain-relieving effect of JTA-004 not only superior to placebo but also

to the active comparator. By identifying three subtypes of OA, amongst which a subtype of OA patients with more severe symptoms and inflammation, this new post-hoc analysis gives a better appreciation for the therapeutic profile of the molecule and potentially allows for the possibility of precisely stratifying patients for a new, optimized Phase III clinical study. BioSenic, which does not intend to allocate R&D resources to support the clinical development of JTA-004 and will continue to focus its R&D activities on the development of its autoimmune (ATO) platform, is seeking to collaborate with existing and potential partners to explore options for the future commercial development of the JTA technology based on this new post-hoc analysis and corresponding new intellectual property rights.

Following the disappointing Phase III clinical results, Biosenic transferred its rights to the JTA technology to the Walloon Region and consequently terminated the license agreement with Glob-Co SRL in 2022. Given the new statistical analysis results from the JTA-004 Phase III clinical trial data obtained in March 2023, the agreement with respect to the to JTA technology (including intellectual property rights forming the JTA-Gen1 patent families) has been since reacquired from the Walloon Region, as the Walloon Region accepted to retrocede its rights to the JTA technology to BioSenic Group in 2023. BioSenic is still discussing the opportunity with Glob-Co SRL to enter into new co-ownership rules for the JTA-Gen1 patent families, the absence of which could give rise to exploitation problems with for the use of the JTA technology and could therefore have a negative impact on BioSenic's possibilities to collaborate with external partners for the future development of the JTA technology.

This section replaces Section 4.12.1.2 "License agreement between Glob-Co and BioSenic regarding the BPBONE-001, BPBONE-002 and BONE-011 patent families (JTA patent families)", ultimate paragraph of the Registration Document:

In March 2023, BioSenic announced that it had used the statistical analysis capabilities of Artialis to study the results of the Phase III JTA-004 trial in the subset of patients with the most painful and inflammatory form of knee osteoarthritis (OA). This allowed BioSenic to distinguish a group of patients, representing about one third of the total patients, who show a pain-relieving effect of JTA-004 not only superior to placebo but also to the active comparator. By identifying three subtypes of OA, amongst which a subtype of OA patients with more severe symptoms and inflammation, this new post-hoc analysis changes the therapeutic profile of the molecule and potentially allows for the possibility of stratifying patients for a new, optimized Phase III clinical study. BioSenic, which does not intend to allocate R&D resources to support the clinical development of JTA-004 and will continue to focus its R&D activities on the development of its autoimmune (ATO) platform, is seeking to collaborate with existing and potential partners to explore options for the future development of JTA-004 based on this new post-hoc analysis.

Following the disappointing Phase III clinical results, Biosenic transferred its rights to the JTA technology to the Walloon Region and consequently terminated the license agreement with Glob-Co SRL in 2022. Given the new statistical analysis results from the JTA-004 Phase III clinical trial data obtained in March 2023, the agreement with respect to the to JTA technology (including intellectual property rights forming the JTA-Gen1 patent families) has been since reacquired from the Walloon Region, as the Walloon Region accepted to retrocede its rights to the JTA technology to BioSenic Group in 2023. BioSenic is still discussing the opportunity with Glob-Co SRL to enter into new co-ownership rules for the JTA-Gen1 patent families, the absence of which could give rise to exploitation problems with for the use of the JTA technology and could therefore have a negative impact on BioSenic's possibilities to collaborate with external partners for the future development of the JTA technology.

This section replaces Section 4.12.1.4 "Loan agreement with the European Investment Bank" of the Registration Document

On 1 July 2021, BioSenic announced that it had signed a loan agreement of up to €16 million with the European Investment Bank (EIB). The EIB financing would support and prepare Bone Therapeutics' lead asset, the enhanced viscosupplement JTA-004 for future regulatory approval and commercialization. JTA-004, was being evaluated in a registrational phase III clinical trial for the treatment of osteoarthritic pain in the knee. Due to the fact that the primary end-points and accompanying objectives of the Phase III results were not met as anticipated, further investments are currently put on hold.

The EIB financing would primarily be used to accelerate the clinical development of ALLOB, BioSenic's scalable allogeneic cell therapy platform. ALLOB is currently being tested in a phase IIb study in patients with difficult-to-heal tibial fractures.

The loan financing has been further supplemented by an agreement to issue warrants to the EIB: 800,000 warrants will be issued with the disbursement of the first tranche and 500,000 warrants with the disbursement of the second tranche. Each warrant will give the holder the right to subscribe to one ordinary share of BioSenic at the subscription price of €0.01 and with an exercise price which will be equal to the minimum of the 30-day volume-weighted average price and the last closing price of BioSenic's shares at the date of the pricing.

The warrants have a maturity of 10 years and become exercisable from the repayment date of the relevant tranche, subject to certain customary exceptions. The warrant agreement further includes an anti-dilution provision which could apply in case of change in BioSenic's share capital, including capital increases if they exceed €15 million in aggregate starting from the disbursement of the first tranche.

The first tranche of €8 million was received on 6 September 2021 (upon approval of the issuance of associated warrants by BioSenic's General Meetings on 23 August 2021).

Given the disappointing results of JTA Phase III published in 2021, the second €8 million tranche has accordingly been excluded in the forward-looking cash projections of BioSenic and new negotiations with the European Investment Bank will need to be scheduled first.

Pursuant to the loan facility, BioSenic is not allowed to incur financial indebtedness towards third parties exceeding €2 million. As of 30 September 2023, such permitted financial indebtedness amounted to €1.4 million.

The loan facility will be in the form of a senior loan, repayable to the EIB in a single payment five years following the disbursement of each of the two tranches. The loan carries a fixed interest of 2% per year paid annually and a 3% capitalized interest.

As of 30 June 2023, the total amount is equal to €8.10 million.

On 14 September 2023, BioSenic announced that it has reached an agreement with the EIB for the restructuring of the loan agreement. The outstanding loan for a principal outstanding amount of EUR 8 million will be extended to 2030, and can be further extended by BioSenic for up to 24 months depending on its cash balance, end of 2032. The interest rate will become 5% per year, payable annually, with an additional non-compounding interest of 3% per year that will be added to the principal amount upon (p)repayment of the loan. The outstanding warrants of the EIB would be cancelled, and EIB should receive a similar return as Monument and Patronale if the latter's new convertible bonds are effectively converted into shares. Completion of the restructuring is still subject to (i) formal EIB approval and (ii) BioSenic raising sufficient new equity for BioSenic to continue its operations including the initiation of the patient treatment in Q2 2024 of a Phase 3 clinical trial of its lead Oral ATO therapeutic candidate targeting cGvHD.

This section replaces Section 4.17.1 "Patents and patent applications owned or licensed by BioSenic " of the Registration Document:

A first panel of BioSenic Group's research programmes and product candidates are covered by patent families (including patents and patent applications still pending and under examination), which were initially either

- filed in the name of Bone Therapeutics and presently owned by BioSenic; or
- licensed by Bone Therapeutics and presently licensed by BioSenic.

The management and maintenance of these patent families are under the responsibility of BioSenic Group. Further details for each program are provided below.

4.17.1.1 ALLOB

The eight patent families related to this program can be associated in two groups:

- Those having an earlier filing date defining the most general features and uses of the cell-based products (**ALLOB-Gen1**), including one patent family owned and exclusively licensed by the ULB to BioSenic Group;

- Those having a later filing date covering features and related to cell manufacturing and medical uses of ALLOB products in cell-based therapies (**ALLOB-Gen2**).

The details of the PCT international patent applications from which the ALLOB patent families are originated, and the main objects of these patent families are summarized below.

Publication No (BioSenic ref. no.)		**Main subject-matter (based on EP pending or granted claims)**
ALLOB-Gen1	WO2007/093431 (ULB-028)	• Methods for obtaining osteoprogenitors or osteoblasts from adult human bone marrow stem cells (BMSC) or adult human mesenchymal stem cells (MSC) in vitro or ex vivo, comprising culturing said BMSC or MSC in a medium including human plasma and/or specific growth factors • Cell populations comprising human osteoprogenitors or osteoblasts that are obtained using such methods and defined by the expression of CD surface markers, cytokines, biological activities and/or differentiation properties • Related pharmaceutical uses and compositions based on such cells
	WO2009/087213 (Bone-001)	
	WO2009/135905 (Bone-002)	
	WO2009/080749 (Bone-004)	Human osteoblasts that are derived by differentiation from BMSC or MSC for autologous or allogeneic administration to human subjects for treating inflammatory rheumatic diseases (IRD, such as systemic lupus erythematosus or rheumatoid arthritis), alone or in combination with anti-inflammatory drugs
ALLOB-Gen2	WO2016/170112 (Bone-013)	In vitro, non-cryogenic preservation from BMSC or MSC for autologous or allogeneic administration to human subjects that apply specific cell culture conditions
	WO2019/076591 (Bone-017)	• Specific methods for obtaining osteoprogenitors or osteoblasts from adult human bone marrow stem cells (BMSC) or adult human mesenchymal stem cells (MSC) in vitro or ex vivo, comprising culturing said BMSC or MSC in a medium including human plasma and/or specific growth factors, in particular for improved cryopreservation • Cell populations comprising human osteoprogenitors or osteoblasts that are obtained using such methods • Related pharmaceutical uses and compositions based upon such cells
	WO2020/064791 (Bone-018)	
	WO2020/064793 (Bone-019)	

The details of the status of the national or regional patent applications that have been filed and prosecuted on the basis of PCT international patent applications for ALLOB-Gen1 patent families are summarized below.

BioSenic ref.	**ULB-028**	**Bone-001**	**Bone-002**	**Bone-004**
PCT no.	WO2007/093431	WO2009/087213	WO2009/135905	WO2009/080749
Priority date	Feb. 2006	Jan. 2008	Jan. 2008	Dec. 2007
Expiry date	Feb. 2027	Jan. 2029	Jan. 2029	Dec. 2028
Europe	Granted (validated in 18 jurisdictions)	Granted (validated in 19 jurisdictions)	Granted (validated in 19 jurisdictions)	Granted (validated in 6 jurisdictions)
USA	Granted	Pending		Granted
Canada	Granted	Granted	Granted	
Australia		Granted	Granted	Granted
Japan	Granted	Granted	Granted	Granted
Singapore	Granted	Granted	Granted	
South Korea		Granted	Granted	Granted
India		Granted		

The details of the status of the national or regional patent applications that have been filed and prosecuted on the basis of PCT international patent applications for ALLOB-Gen2 patent families are summarized below.

BioSenic ref.	**Bone-013**	**Bone-017**	**Bone-018**	**Bone-019**
PCT no.	WO2016/170112	WO2019/076591	WO2020/064791	WO2020/064793
Priority date	Apr. 2015	Oct. 2017	Sep. 2018	Sep. 2018
Expiry date	Apr. 2036	Sep. 2038	Sep. 2039	Sep. 2039
Europe	Granted (validated in 6 jurisdictions)	Pending (near to be granted)	Granted (validated in 20 jurisdictions)	Pending (near to be granted)
Belgium	Granted	Granted	Granted	Granted
USA		Granted (divisional appl. still pending)	Pending	Pending
Canada	Granted	Granted	Pending	
Australia	Granted	Granted	Pending	Pending
China		Pending	Pending	Pending
Japan	Granted	Granted	Pending	Pending
Taiwan			Pending	
Singapore	Granted	Granted	Pending	Pending
South Korea	Granted	Granted	Pending	Pending
India		Pending	Pending	
Thailand		Pending	Pending	Pending
Mexico			Pending	
Brazil		Pending	Pending	
Russia		Pending	Pending	
Israel		Granted	Pending	

4.17.1.2 JTA

The five patent families related to this program can be associated in two groups:

- Those having an earlier filing date defining the most general features and uses of JTA technology (**JTA-Gen1**) and co-owned with Glob-Co SRL;

- Those having a later filing date covering more recent development in manufacturing and uses of JTA technology in clinical settings (**ALLOB-Gen2**).

The details of the PCT international patent applications and EP priority patent applications from which the ALLOB patent families are originated, and the object of these patent families are summarized below.

Publication No (Int. code)		Main subject-matter (based on EP pending or granted claims)
JTA-Gen1 (co-owned with Glob-Co)	WO2009/101194 (BPBone-01)	• Preparation and use of pharmaceutical formulations comprising hyaluronic acid, and one or more other anti-inflammatory drugs, such as clonidine, for treating musculoskeletal diseases (with or without adding cells) • These pharmaceutical formulations specific methods of administration of these pharmaceutical formulations
	WO2009/101210 (BPBone-02)	
	WO2014/049063 (Bone-011)	• Preparation of pharmaceutical formulations comprising pre-treated preparations of plasmatic proteins, hyaluronic acid, and optionally one or more other products, such as clonidine, cells, growth factors • The resulting pharmaceutical formulations and their use for treating musculoskeletal diseases such as bone or joint disease
JTA-Gen2	WO2020/229526 (Bone-020)	• Preparation of lyophilized pharmaceutical formulations comprising pre-treated preparations of plasmatic proteins, hyaluronic acid, and optionally one or more other products, such as clonidine, cells, growth factors • The resulting lyophilized pharmaceutical formulations and their use for treating musculoskeletal diseases such as bone or joint disease
	EP2023nnnnnnn (ClinJTA)	• Use of products based on JTA technology such as JTA-004 in specific patients' group affected by knee osteoarthritis • Methods to define most effective products based upon JTA technology that are suitable for treating subjects affected by osteoarthritis

The details of the status of the national or regional patent applications that have been filed and prosecuted on the basis of PCT international patent applications for JTA-Gen1 and JTA-Gen2 patent families are summarized below. ClinJTA patent family is presently pending only as EP priority patent application and the decision about filing the corresponding PCT international patent application will be taken in 2024.

BioSenic ref. no.	**JTA-Gen1**			**JTA-Gen2**
	BPBone-01	**BPBone-02**	**Bone-011**	**Bone-020**
PCT no.	WO2009/101194	WO2009/101210	WO2014/049063	WO2020/229526
Priority date	Feb. 2008	Feb. 2008	Sep. 2012	May 2019
Expiry date	Feb. 2029	Feb. 2029	Sep. 2033	May 2040
Europe	Granted (validated in 18 jurisdictions)	Granted (validated in 5 jurisdictions)	Granted (validated in 18 jurisdictions)	Pending
Belgium	Granted		Granted	Granted
USA	Granted	Granted (2 patents)	Granted	Pending
Canada	Granted	Granted	Granted	Pending
Australia	Granted	Granted	Granted	
China	Granted		Granted (divisional appl. still pending)	Pending
Japan	Granted	Granted	Pending	Pending
Taiwan				Pending
Singapore	Granted	Granted	Granted	
South Korea	Granted		Granted	Pending
India	Granted	Granted		
Brazil	Granted			
Israel	Granted	Granted	Granted	Pending

This section replaces Section 4.17.2 "Overview of intellectual property owned or licensed by Medsenic" of the Registration Document:

A second panel of BioSenic Group's research programmes and product candidates are covered by patent families (including patents and patent applications still pending and under examination), which were either:

- filed in the name of Medsenic; or

- licensed by Medsenic.

Unless indicated otherwise, the management and maintenance of these patent families are under the responsibility of Medsenic. Further details for each program are provided below.

4.17.2.1 Patent families filed by Medsenic

The details of the PCT international patent applications and of the EP priority patent application, and the main objects of these patent families are summarized below.

Publication No (BioSenic ref. no.)	Main subject-matter (based on EP pending or granted claims)
WO2018/206465 (MEDS-01)	Methods for preventing, delaying, or treating multiple sclerosis, in particular relapsing-remitting multiple sclerosis and Graft-vs-Host-Disease, using arsenic trioxide
WO2020/234414 (MEDS-02)	Combination of an arsenic compound and a metal (in particular copper) for increasing the effects of arsenic for treating cancers, autoimmune or inflammatory diseases
WO2021/198535 (MEDS-03)	Use of an arsenic compound, alone or combined with a metal (in particular copper), for treating a cytokine storm (as after SARS-CoV-2 infection)
EP23nnnnnn (MEDS-04)	In vitro methods for the diagnosis, prognosis, stratification and/or monitoring of chronic graft-versus-host disease in an individual who has received an allogeneic hematopoietic stem cell transplantation alone or in combination with other drugs (such as an arsenic compound)

The details of the status of the national or regional patent applications that have been filed and prosecuted on the basis of PCT international patent applications for MEDS-01, MEDS-02, and MEDS-03 patent families are summarized below. MEDS-04 patent family is presently pending only as EP priority patent application and the decision about filing the corresponding PCT international patent application will be taken in 2024.

BioSenic ref. no.	MEDS-01	MEDS-02	MEDS -03
PCT no.	WO2018/206465	WO2020/234414	WO2021/198535
Priority date	May 2017	May 2018	Apr. 2020
Expiry date	May 2038	May 2039	Apr. 2041
Europe	Pending	Granted (validated in 8 jurisdictions)	Pending
USA	Granted	Pending	Pending
Canada		Pending	Pending
Australia		Pending	Pending
China	Pending	Granted	
Japan		Pending	
Russia		Pending	

4.17.2.2 Patent families licensed by Medsenic

The details of the PCT international patent applications and of the EP priority patent application, and the main objects of these patent families are summarized below. Related cost and management are under the responsibility of filing entities (Phebra, Australia; CNRS, France).

Publication No (Int. code)		Main subject-matter (based on EP pending or granted claims)
Licensed from Phebra	WO2016/119019 (PHEB-01)	Highly soluble arsenic carbonate and/or bicarbonate compound for preparing pharmaceutical combination (in particular using a process starting from arsenic trioxide) as a solid, orally deliverable, bioequivalent form of arsenic trioxide solution, in particular to be used in the treatment of cancers
	WO2018/098519 (PHEB-02)	Solid, orally deliverable, pharmaceutical composition comprising a diarsenic tetraoxide, in particular to be used in the treatment of cancers

Licensed from CNRS	WO2003/090766 (CNRS-01)	Use of an arsenic compound (such an arsenic oxide and related salts) for treating autoimmune or inflammatory diseases, such as Graft-versus-host disease, rheumatoid arthritis, or Sjogren's Syndrom

The details of the status of the national or regional patent applications that have been filed and prosecuted on the basis of PCT international patent applications for PHEB-01, PHEB-02, and CNRS-01 patent families are summarized below.

BioSenic ref. no.	**PHEB-01**	**PHEB-02**	**CNRS -01**
PCT no.	WO2016/119019	WO2018/098519	WO2003/090766
Priority date	Jan. 2015	Dec. 2016	Apr. 2002
Expiry date	Jan. 2036	Aug. 2037	Apr. 2023
Europe	Granted (validated in 17 jurisdictions)	Granted (validation still ongoing; 11 jurisdictions until today)	Expired
USA	Granted	Granted	Granted (2 patents extended until 2031 for Graft-versus-host disease and 2030 for lupus erythematosus)
Canada	Granted	Pending	Expired
Australia	Granted	Granted	
China	Granted	Pending	
Japan	Granted	Granted	
New Zealand	Granted	Granted	
Singapore	Granted	Granted	
Taiwan		Granted	
South Korea	Pending (allowed in Sept. 2023)	Granted	
India	Granted		
Mexico	Granted	Granted	
Peru		Pending	
Chile		Granted	
Brazil	Pending	Pending	
Israel	Granted	Granted	
Saudi Arabia		Pending	
UAE		Pending	
South Africa	Granted	Granted	

This section replaces Section 4.17.3 " Trademarks and designs of BioSenic " of the Registration Document:

4.17.3 Trademarks and designs of BioSenic

BioSenic Group obtained the trademark registration for Biosenic, under class 5 in the Benelux, the EU, France, Great Britain, USA, Japan, China, Australia, and Canada.

BioSenic Group obtained the trademark registration for the following trademarks initially filed by Bone Therapeutics:

- ALLOB was internationally registered under class 5 and/or class 42 in the Benelux, the EU, USA, Australia, Canada, Israel, Japan, Taiwan, Hong Kong, Singapore, Thailand, and South Korea;
- JOINTAIC was internationally registered under class 5 and/or class 42 in the Benelux, the EU, Great Britain, Hong-Kong, Japan, China, Australia, and South Korea;

- MaxBone was internationally registered under class 5 and/or class 42 in the Benelux, the EU, Great Britain, Canada, Japan, China, Hong-Kong, and Australia;
- MXB was internationally registered under class 5 and/or class 42 was obtained in September 2015 in EU, US, Japan, Korea, Australia, Canada, Israel and Hong Kong;
- JTA was internationally registered under class 5 and/or class 42 was obtained in September 2015 in the Benelux, the EU, Japan, Korea, China, Australia, Canada, Israel and Hong Kong.

This section replaces Section 6.4 "Board of Directors" of the Registration Document:

Section 6.4 has been updated through the annual report for the financial year ended 31 December 2022, which is available on the BioSenic's website via the following hyperlink: https://www.biosenic.com/node/645 (the "**Annual Report 2022**"). Please find the update in Section 4.3 "Board of Directors" of the Annual Report 2022, which is included herein by reference.

This section replaces Section 6.5 "Executive Committee" of the Registration Document:

Section 6.5 has been updated through the Annual Report 2022: please find the update in Section 4.4 "Executive Committee" of the Annual Report 2022, which is included herein by reference.

This section replaces Section 6.8 "Remuneration report" of the Registration Document:

Section 6.8 has been updated through the Annual Report 2022: please find the update in Section 4.7 "Remuneration report" of the Annual Report 2022, which is included herein by reference.

Update of section 9.3.2 "Summary of the outstanding warrant plans"

In Section 9.3.2, paragraph 4, reference is made to the terms and conditions of the ALLOB warrants of BioSenic. This paragraph, as well as any other reference to the ALLOB warrants in the Registration Document, is deemed to be deleted from the Registration Document as the ALLOB warrants were cancelled following the announcement by the Company on 19 June 2023 that the primary endpoint of the ALLOB Phase IIb clinical trial was not reached and that the triggering event for the ALLOB warrants has therefore not occurred.